You are here

  • Home
  • Online First
  • Large and middle hepatitis B surface antigen: the lower the better?

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Letter
Large and middle hepatitis B surface antigen: the lower the better?
  1. Hsuan-Ho Lin1,
  2. Tai-Chung Tseng1,2,
  3. Jia-Horng Kao2,3,4
  1. 1Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  2. 2Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan
  3. 3Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
  4. 4Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
  1. Correspondence to Professor Jia-Horng Kao, Hepatitis Research Center, National Taiwan University Hospital, Taipei 10002, Taiwan; kaojh{at}ntu.edu.tw

https://doi.org/10.1136/gutjnl-2018-316030

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article entitled ‘Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers’ by Pfefferkorn et al.1 Serum hepatitis B surface antigen (HBsAg) level has been shown to complement HBV DNA level in predicting clinical outcomes of patients with chronic HBV infection.2 3 In Asian patients, mostly genotype B and C infection, with a low viral load (HBV DNA  ≤2000 IU/mL), HBsAg level >1000 IU/mL indicates …

    View Full Text

    Footnotes

    • Contributors HHL and TCT drafted the manuscript. JHK did the critical review of the manuscript.

    • Funding This work was supported by the grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST 105-2314-B-303-008).

    • Competing interests JHK is the consultant for Abbvie, Bristol-Myers Squibb and Gilead Sciences; on speaker’s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences and Merck.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; internally peer reviewed.